Avidity Advances in FSHD, Insmed Passes PAH Test, Merck Delivers with Oral PCSK9

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.